Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
Phase of Trial: Phase I/II
Latest Information Update: 05 Nov 2018
At a glance
- Drugs LB 100 (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 05 Nov 2018 According to Lixte Biotechnology Holdings media release, the FDA approved the IND application to conduct this study. The trail will be conducted at the Moffitt Cancer Center, Tampa, FL.
- 09 Oct 2018 According to Lixte Biotechnology Holdings media release, IND has been submitted.
- 05 Sep 2018 New trial record